Continuing CDK4/6 inhibitor therapy and switching ET after disease progression does not improve progression-free survival vs switching ET alone in HR+, HER2- metastatic breast cancer.
Adding capivasertib to treatment with fulvestrant improved progression-free survival in aromatase inhibitor-resistant, HR+, HER2- advanced breast cancer.
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.
Patients with HR+/HER2-, intermediate-risk, early breast cancer can forgo chemotherapy without increasing their risk of late recurrence, updated data suggest.
Adding abemaciclib to adjuvant endocrine therapy can provide long-term benefits for patients with high-risk, HR+, HER2- early breast cancer, updated data suggest.